about
Novel oral anticoagulants and the 73rd anniversary of historical warfarinChemoenzymatic synthesis of heparan sulfate and heparinSpecial considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillationPharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolismComparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD.Homogeneous low-molecular-weight heparins with reversible anticoagulant activity.Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation.Patient safety issues in CKD: core curriculum 2015.Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.Anticoagulation in heart failure: current status and future direction.Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations.Use of new oral anticoagulants in antiphospholipid syndrome.Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation.Synthetic oligosaccharides can replace animal-sourced low-molecular weight heparins.
P2860
Q26771544-931FF652-9D91-4D9C-ADCF-5F5640DAD448Q27005958-B4ED6050-0D84-466D-A5D2-7BE243544320Q28072542-B27D350F-15B0-4BFB-BDF8-61851176E021Q28087447-52EB3DB0-4307-43E0-8C11-123AA60B1E11Q35079761-7165B7B2-A2F7-4E33-AB83-A65015A7A294Q35361517-8F53BE68-2085-4264-9911-79B9B8C39CF5Q35746798-71DAABD2-44D8-42B6-812A-8F8B20616964Q35798287-26BF6ADD-C024-4B09-ADA2-C50C477743C5Q38029077-CEEB1A58-C1C9-490F-B696-C6F25CC59D0DQ38044305-9A56D0EC-7641-484D-AB1F-022962324E95Q38079779-1B6AFC68-3511-42CF-90B0-69537C0A5013Q38091327-C590DFF0-469D-4B15-ABBB-6A2734779688Q38104683-F31C1167-D0F5-4B6E-9900-518CA362B180Q38164313-EFE6A15A-D4CF-42AB-AE5E-B60A7C7BF4D2Q47189835-46590F10-3F05-49EB-A4FA-1A3954E4AF7C
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Renal profiles of anticoagulants.
@en
Renal profiles of anticoagulants.
@nl
type
label
Renal profiles of anticoagulants.
@en
Renal profiles of anticoagulants.
@nl
prefLabel
Renal profiles of anticoagulants.
@en
Renal profiles of anticoagulants.
@nl
P2860
P356
P1476
Renal profiles of anticoagulants.
@en
P2093
Sebastian Harder
P2860
P304
P356
10.1177/0091270011409231
P577
2011-05-24T00:00:00Z